Anixa Biosciences Announces Opening Of Enrollment For Keytruda Arm In Ongoing Breast Cancer Vaccine Clinical Trial
Portfolio Pulse from Happy Mohamed
Anixa Biosciences has announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of Anixa's breast cancer vaccine with Keytruda, a therapy marketed by Merck. This is an expansion of the ongoing Phase 1 dose escalation trial of Anixa's breast cancer vaccine. The aim is to determine if the vaccine/Keytruda combination increases immune response.
August 07, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences is expanding its Phase 1 trial to include a combination of its breast cancer vaccine with Merck's Keytruda. This could potentially enhance the effectiveness of Anixa's vaccine.
The news of the expansion of the Phase 1 trial to include a combination of Anixa's vaccine with Keytruda is positive for Anixa. If successful, this could enhance the effectiveness of Anixa's vaccine, potentially leading to increased demand and revenue.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's Keytruda is being used in combination with Anixa's breast cancer vaccine in an expanded Phase 1 trial. This could potentially increase the use cases for Keytruda.
The news of Keytruda being used in combination with Anixa's vaccine in an expanded Phase 1 trial is positive for Merck. If successful, this could increase the use cases for Keytruda, potentially leading to increased demand and revenue.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70